Kiwoom Securities Lowers GC Pharma Target Price to 190,000 Won... Impact of Revenue Recognition Timing
Kiwoom Securities has lowered its target price for GC Pharma from 210,000 won to 190,000 won, anticipating its second-quarter earnings to fall short of market expectations. However, the brokerage maintained its 'buy' rating, attributing the anticipated performance dip primarily to the timing of revenue recognition rather than a slowdown in demand.
Key takeaway
"Kiwoom Securities Lowers GC Pharma Target Price to 190,000 Won... Impact of Revenue Recognition Timing" — BullBear's AI rates this story as a bearish (negative) signal for markets, with a market-impact score of 60 out of 100. Kiwoom Securities has lowered its target price for GC Pharma from 210,000 won to 190,000 won, anticipating its second-quarter earnings to fall short of market expectations. However, the brokerage maintained its 'buy' rating, attributing the anticipated performance dip primarily to the timing of revenue recognition rather than a slowdown in demand. Reported by TokenPost on July 21, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bear flag
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 51.9%.